Welcome to our dedicated page for Tharimmune SEC filings (Ticker: THAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tharimmune, Inc. (NASDAQ: THAR) SEC filings page on Stock Titan aggregates the company’s official disclosures filed with the U.S. Securities and Exchange Commission, including its Current Reports on Form 8-K, proxy materials, and other registration documents. These filings provide primary-source detail on Tharimmune’s clinical-stage biotechnology programs and its Canton Coin-focused digital asset treasury strategy.
Recent Form 8-K filings describe material definitive agreements such as securities purchase agreements for private placements involving common stock and pre-funded warrants, as well as an at-the-market sales agreement for common stock. They also outline the structure and intended use of proceeds from offerings designed to support both Tharimmune’s historical biotech operations and the establishment of a Canton Coin treasury and related Canton Network participation.
Other 8-Ks and proxy materials detail corporate governance and compensation matters, including amendments to the certificate of incorporation to increase authorized common stock, changes to the omnibus equity incentive plan, and the appointment of key executives such as the Chief Executive Officer, President, and Chief Financial Officer. These documents specify employment agreement terms, severance provisions, and equity award structures for senior leadership associated with the company’s biotechnology and digital asset initiatives.
Investors can also use this page to access risk factor discussions related to Tharimmune’s Canton Coin strategy, as described in its filings, including risks tied to digital asset volatility, regulatory uncertainty, and liquidity considerations. Proxy statements provide additional context on share authorization proposals and future offering authorizations under Nasdaq rules.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, capital structure changes, and leadership updates, helping readers quickly interpret complex legal and financial language. From here, you can review Tharimmune’s 8-Ks, registration statements, and proxy materials, and use the platform’s tools to track insider-related disclosures and ongoing financing arrangements as they appear in the EDGAR feed.
Canton Strategic Holdings, Inc. is undergoing a major shift from a traditional biotechnology business to a Canton Coin (CC)–focused digital asset treasury and Canton Network participation strategy. The company now prioritizes acquiring, holding and deploying CC, including validator operations and token management.
It still runs clinical-stage biotech programs such as GV104, a buccal nalmefene film for opioid exposure being advanced via the 505(b)(2) pathway, and GV023, an oral infliximab program licensed from Intract. Recent financings include a $545 million November 2025 PIPE and a $54.9 million January 2026 underwritten offering, plus an ATM program allowing up to $300 million of additional stock sales. Management and board changes in late 2025 and early 2026 align leadership with the new CC-centric strategy, which carries significant regulatory, market, custody and volatility risks that could materially affect results and the stock price.
Canton Strategic Holdings reported its first full-year results since adopting a Canton Network–focused digital asset strategy. The company raised $545 million in a November 2025 private placement to build a large Canton Coin (CC) treasury and support its role on the Canton Network.
As of December 31, 2025, Canton Strategic held 3,339,569,946 CC with a fair value of $501,760,369 and had $17 million in cash, but has not recognized any revenue since inception. Operating expenses rose to $20.1 million in 2025 from $12.4 million in 2024, driven by the digital asset transition and $6 million of non-recurring compensation.
The company recorded an unrealized loss on digital assets of $22.0 million, contributing to a 2025 net loss of $35.9 million, or ($1.12) per diluted share, versus a $12.2 million loss, or ($9.41), in 2024. It reported an accumulated deficit of $72.8 million. Early 2026 steps included a $55 million underwritten equity offering, an at-the-market program, and approval to operate as a Super Validator on a network processing over one million daily transactions and more than $9 trillion in monthly volume.
Canton Strategic Holdings, Inc. entered into an amended and restated at-the-market sales agreement with Clear Street LLC and Virtu Americas LLC to sell shares of its common stock from time to time. The agreement provides for an aggregate gross sales price of up to $300,000,000 of common stock, excluding shares previously sold under the prior agreement.
Sales will be made under the company’s effective Form S‑3 shelf registration and related prospectus supplement, through at-the-market transactions, negotiated deals or block trades, as permitted by law. The sales agents will use commercially reasonable efforts, earn commissions of up to 3.00% of gross proceeds, and either party can suspend or terminate the offering.
Canton Strategic Holdings, Inc. is registering an at-the-market offering to sell up to $300,000,000 of its common stock under an amended Sales Agreement with Clear Street LLC and Virtu Americas LLC, permitting sales from time to time through or to the Sales Agents.
The program amends an earlier ATM arrangement, follows prior issuances including a January registered offering and a November PIPE, and permits negotiated or Rule 415(a)(4) at-the-market sales with commissions up to 3.0% of gross proceeds; timing and amounts sold are subject to the Sales Agreement terms.
Canton Strategic Holdings, Inc. reported that its Chairman and Chief Executive Officer, Mark Wendland, has been elected to the Board of Directors of the Canton Foundation. This is described as underscoring the company’s leadership role in helping accelerate institutional adoption of the Canton Network.
The Canton Foundation is the independent governance body overseeing operation, standards, the validator framework, and policies related to the Global Synchronizer and broader Canton Network operations. With Wendland joining 17 existing Board members from major global financial institutions, Canton Strategic Holdings also becomes a Premier Member of the Foundation, deepening its alignment with the Foundation’s mission to support growth and governance of the Canton Network.
Canton Strategic Holdings, Inc., formerly Tharimmune, Inc., has completed a corporate rebrand to align with its digital asset treasury strategy focused on the Canton Network. The company changed its legal name and amended its charter and bylaws, and its NASDAQ ticker is moving from “THAR” to “CNTN” effective February 18, 2026.
The press release highlights that the company was established in November 2025 through a $545 million private placement and is pursuing value creation via Canton Coin acquisition, operating a Super Validator, and investing in applications that support institutional adoption of the Canton Network. Recent milestones include approval as a Super Validator, additions of institutional leaders such as former CFTC Commissioner Jill Sommers and DRW Chief of Staff William Wiley to the board, and closing a $55 million underwritten registered offering to fund further growth. The company also continues to operate clinical-stage biotech research and development alongside its digital asset activities.
Tharimmune, Inc. officer Angela Dominy Radkowski, the company’s Chief Operating Officer, filed an initial insider ownership report. As of the event date of 02/05/2026, she reports that no Tharimmune securities are beneficially owned. The filing is made solely by this one reporting person.
Tharimmune, Inc. director Jill E. Sommers filed a Form 3 reflecting her status as a director and indicating that she beneficially owns no securities of Tharimmune. The filing is dated for an event on January 30, 2026 and is filed by one reporting person.
Tharimmune, Inc. director William Thomas Wiley Jr. filed an initial ownership report stating that he beneficially owns no securities of the company as of the event date of January 30, 2026. The filing lists no non-derivative or derivative holdings and reports no transactions.
Tharimmune, Inc. executive Jacob Asbury, the company’s Chief Financial Officer, filed an initial ownership report on Form 3. The filing states that no securities of Tharimmune are beneficially owned, meaning he reported holding no company shares or derivative securities as of the reported event date.